Identification of novel risk loci for restless legs syndrome in genome-wide
In October 2017 appeared in Lancet Neurology (Lancet Neurol. 2017 Nov;16(11):898-907. doi: 10.1016/S1474-4422(17)30327-7) article “Identification of novel risk loci for restless legs syndrome in genome-wide association studies in individuals of European ancestry: a meta-analysis“ on which participated also three colleagues from Czech Republic, between them Pavel Vodicka from Institute of Experimental Medicine. In this large, comprehensive study were combined several GWAS datasets involving 15 126 cases and 95 725 controls of European ancestry and significant results were verified an independent GWAS of 30 770 cases and 286 913 controls. It was identified and replicated 13 new risk loci for restless legs syndrome and confirmed the previously identified six risk loci. Identification of new candidate genes and associated pathways will inform future functional research. Advances in understanding of the molecular mechanisms that underlie restless legs syndrome could lead to new treatment options. Morover knowledge brought by this study leads to understanding of many processes involved in cell life-span (as DNA repair).